R&G PharmaStudies Co. Ltd. A (SHE:301333) — Stock Price
R&G PharmaStudies Co. Ltd. A (SHE:301333) is currently trading at CN¥58.00 CNY, up 2.09% today. Over the past 52 weeks, shares have ranged between CN¥44.50 and CN¥91.20. This page tracks R&G PharmaStudies Co. Ltd. A's live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 301333 market cap.
R&G PharmaStudies Co. Ltd. A (301333) Stock Price Chart — Daily History & Trading Volume
The chart below tracks R&G PharmaStudies Co. Ltd. A's daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.
R&G PharmaStudies Co. Ltd. A Income Statement — Revenue, Profit & Earnings by Year
R&G PharmaStudies Co. Ltd. A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥851.01 Million | CN¥744.00 Million | CN¥721.37 Million | CN¥637.52 Million | CN¥608.43 Million |
| Cost of Revenue | CN¥555.36 Million | CN¥468.08 Million | CN¥434.34 Million | CN¥402.62 Million | CN¥375.25 Million |
| Gross Profit | CN¥295.64 Million | CN¥275.92 Million | CN¥287.04 Million | CN¥234.90 Million | CN¥233.17 Million |
| Research & Development | CN¥61.97 Million | CN¥56.83 Million | CN¥52.86 Million | CN¥49.99 Million | CN¥41.19 Million |
| SG&A | CN¥64.04 Million | CN¥55.35 Million | CN¥55.93 Million | CN¥37.23 Million | CN¥38.25 Million |
| Total Operating Expenses | CN¥715.99 Million | CN¥613.52 Million | CN¥573.03 Million | CN¥525.47 Million | CN¥488.29 Million |
| Operating Income | CN¥135.02 Million | CN¥130.49 Million | CN¥148.35 Million | CN¥112.05 Million | CN¥120.14 Million |
| EBITDA | — | — | — | CN¥164.41 Million | CN¥150.81 Million |
| EBIT | — | — | — | — | — |
| Interest Expense | CN¥2.86 Million | CN¥3.44 Million | CN¥600.74K | CN¥672.95K | CN¥580.70K |
| Income Before Tax | CN¥155.15 Million | CN¥157.79 Million | CN¥182.47 Million | CN¥128.89 Million | CN¥113.60 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CN¥136.90 Million | CN¥140.22 Million | CN¥162.53 Million | CN¥113.45 Million | CN¥99.24 Million |
R&G PharmaStudies Co. Ltd. A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes R&G PharmaStudies Co. Ltd. A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥2.40 Billion | CN¥2.34 Billion | CN¥2.07 Billion | CN¥1.88 Billion | CN¥677.47 Million |
| Total Current Assets | CN¥2.16 Billion | CN¥2.13 Billion | CN¥2.01 Billion | CN¥1.81 Billion | CN¥605.11 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥620.12 Million | CN¥707.61 Million | CN¥712.39 Million | — | — |
| Net Receivables | CN¥133.47 Million | CN¥125.24 Million | CN¥90.00 Million | CN¥72.87 Million | CN¥73.73 Million |
| Inventory | CN¥59.02 Million | CN¥65.23 Million | CN¥51.26 Million | CN¥53.01 Million | CN¥43.27 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | CN¥85.60 Million | CN¥85.60 Million | CN¥83.84K | CN¥83.84K | CN¥83.84K |
| Total Liabilities | CN¥423.89 Million | CN¥500.09 Million | CN¥319.17 Million | CN¥289.35 Million | CN¥239.66 Million |
| Total Current Liabilities | CN¥385.07 Million | CN¥436.49 Million | CN¥314.36 Million | CN¥280.52 Million | CN¥234.43 Million |
| Long-term Debt | — | — | — | CN¥0.00 | CN¥0.00 |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | CN¥1.97 Billion | CN¥1.83 Billion | CN¥1.75 Billion | CN¥1.59 Billion | CN¥422.53 Million |
| Retained Earnings | CN¥801.09 Million | CN¥686.76 Million | CN¥569.26 Million | CN¥428.65 Million | CN¥344.16 Million |
R&G PharmaStudies Co. Ltd. A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how R&G PharmaStudies Co. Ltd. A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥114.20 Million | CN¥154.76 Million | CN¥192.56 Million | CN¥130.47 Million | CN¥114.57 Million |
| Capital Expenditures | CN¥19.28 Million | CN¥19.98 Million | CN¥19.88 Million | CN¥20.83 Million | CN¥38.28 Million |
| Free Cash Flow | CN¥94.93 Million | CN¥134.78 Million | CN¥172.68 Million | CN¥109.64 Million | CN¥76.29 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | CN¥11.78 Million | CN¥28.38 Million | CN¥5.82 Million | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CN¥35.61 Million | CN¥36.31 Million | CN¥34.57 Million | CN¥34.85 Million | CN¥36.05 Million |
| Change in Cash | CN¥60.56 Million | CN¥63.44 Million | CN¥-529.69 Million | CN¥1.16 Billion | CN¥67.77 Million |
R&G PharmaStudies Co. Ltd. A Earnings History — EPS Actual vs. Analyst Estimates
Track R&G PharmaStudies Co. Ltd. A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 0.24 | — | — |
| Mar 28, 2026 | 0.43 | — | — |
| Oct 29, 2025 | 0.36 | — | — |
| Aug 28, 2025 | 0.37 | — | — |
| Apr 27, 2025 | 0.27 | — | — |
| Mar 28, 2025 | 0.59 | — | — |
| Oct 29, 2024 | 0.27 | — | — |
| Aug 29, 2024 | 0.37 | — | — |